FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report of Foreign
Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For September
2008
Commission File
Number: 001-11960
AstraZeneca
PLC
15 Stanhope Gate,
London W1K 1LN, England
Indicate by check
mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Form 20-F X
Form
40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number assigned to the Registrant in
connection with Rule 12g3-2(b): 82-_____________
AstraZeneca
PLC
INDEX TO
EXHIBITS
|
1.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 1 September
2008.
|
|
2.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 2 September
2008.
|
|
3.
|
Press release
entitled, Repurchase of Shares in AstraZeneca PLC “”, dated 3 September
2008.
|
|
4.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 4 September
2008.
|
|
5.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 5 September
2008.
|
|
6.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC ”, dated 8 September
2008.
|
|
7.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 9 September
2008.
|
|
8.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 10 September
2008.
|
|
9.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 11 September
2008.
|
|
10.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 12 September
2008.
|
|
11.
|
Press release
entitled, “AstraZeneca PLC Appoints New Non-Executive Director”, dated 12
September 2008.
|
|
12.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 15 September
2008.
|
|
13.
|
Press release
entitled, “AstraZeneca and Targacept Announce Top-Line Results From Phase
IIB Study of AZD3480 in Alzheimer’s Disease”, dated 16 September
2008.
|
|
14.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 16 September
2008.
|
|
15.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 17 September
2008.
|
|
16.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 18 September
2008.
|
|
17.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 19 September
2008.
|
|
18.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 22 September
2008.
|
|
19.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC ”, dated 23 September
2008.
|
|
20.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC ”, dated 24 September
2008.
|
|
21.
|
Press release
entitled, “US Court Denies Teva’s Motion for Summary Judgment in Pulmicort
Respules Patent Litigation”, dated 24 September
2008.
|
|
22.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 25 September
2008.
|
|
23.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 26 September
2008.
|
|
24.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 29 September
2008.
|
|
25.
|
Press release
entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 30 September
2008.
|
|
26.
|
Press release
entitled, “AstraZeneca PLC Irrevocable, Non-Discretionary Share Repurchase
Programme”, dated 30 September
2008.
|
|
27.
|
Press release
entitled, “Transparency Directive Voting Rights and Capital”, dated 30
September 2008
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
| |
AstraZeneca
PLC |
|
| |
|
|
|
|
| |
|
|
|
|
|
Date: 2
October 2008
|
By: |
/s/ Justin
Hoskins |
|
|
|
|
Name: |
Justin
Hoskins
|
|
|
|
|
Title: |
Deputy
Company Secretary
|
Item 1
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 185,294
ordinary shares of AstraZeneca PLC at a price of 2695 pence per share on 29
August 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,451,498,236.
G H R
Musker
Company
Secretary
1 September
2008
Item 2
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 183,035
ordinary shares of AstraZeneca PLC at a price of 2726 pence per share on 1
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,451,324,661.
G H R
Musker
Company
Secretary
2 September
2008
Item 3
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 179,781
ordinary shares of AstraZeneca PLC at a price of 2771 pence per share on 2
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,451,180,251.
G H R
Musker
Company
Secretary
3 September
2008
Item 4
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 183,600
ordinary shares of AstraZeneca PLC at a price of 2719 pence per share on 3
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,451,101,626.
G H R
Musker
Company
Secretary
4 September
2008
Item 5
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 188,405
ordinary shares of AstraZeneca PLC at a price of 2654 pence per share on 4
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,450,933,010.
G H R
Musker
Company
Secretary
5 September
2008
Item 6
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 190,889
ordinary shares of AstraZeneca PLC at a price of 2619 pence per share on 5
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,450,742,121.
G H R
Musker
Company
Secretary
8 September
2008
Item 7
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 192,061
ordinary shares of AstraZeneca PLC at a price of 2603 pence per share on 8
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,450,550,060.
G H R
Musker
Company
Secretary
9 September
2008
Item 8
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 189,094
ordinary shares of AstraZeneca PLC at a price of 2644 pence per share on 9
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,450,360,966.
G H R
Musker
Company
Secretary
10 September
2008
Item 9
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 189,740 ordinary shares of
AstraZeneca PLC at a price of 2635 pence per share on 10
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,450,175,561.
G H R
Musker
Company
Secretary
11 September
2008
Item 10
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 195,658
ordinary shares of AstraZeneca PLC at a price of 2554 pence per share on 11
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,449,980,725.
G H R
Musker
Company
Secretary
12 September
2008
Item 11
ASTRAZENECA
PLC APPOINTS NEW NON-EXECUTIVE DIRECTOR
AstraZeneca today
announced that Rudy Markham is to join the Board of Directors as a Non-Executive
Director with immediate effect. Rudy Markham was formerly Chief
Financial Officer of Unilever. He is currently a Non-Executive
Director of Legal and General Group Plc, Standard Chartered PLC and United
Parcel Service, Inc. He is also a member of Board of the Financial
Reporting Council.
Louis Schweitzer,
Chairman of AstraZeneca said: “We are delighted that Rudy Markham has agreed to
join us. His considerable experience of over 35 years at Unilever,
latterly in finance, will be invaluable to the work of the Board and the Audit
Committee.”
No disclosure
obligations arise under paragraph (1) to (6) of Listing Rule 9.6.13 of the UK
Listing Authority’s Listing Rules in respect of the appointment of Rudy
Markham.
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in research, development,
manufacturing and marketing of prescription pharmaceuticals and supplier for
healthcare services. AstraZeneca is one of the world's leading pharmaceutical
companies with healthcare sales of US $29.55 billion and is a leader in
gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and
infection product sales. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index.
|
Media
Enquiries:
|
|
|
Neil
McCrae
|
+44 207 304
5045 (24 hours)
|
|
Chris
Sampson
|
+44 20 7304
5130 (24
hours)
|
|
Investor
Enquiries UK:
|
|
|
Jonathan
Hunt
|
+44 207 304
5087
|
mob: +44 7775
704032
|
|
Mina
Blair
|
+44 20 7304
5084
|
mob: +44 7718
581021
|
|
Karl
Hard
|
+44 207 304
5322
|
mob: +44 7789
654364
|
|
Investor
Enquiries US:
|
|
|
Ed
Seage
|
+1 302 886
4065
|
mob: +1 302
373 1361
|
|
Jorgen
Winroth
|
+1 212 579
0506
|
mob: +1 917
612 4043
|
|
Peter Vozzo
(MedImmune)
|
+1 301 398
4358
|
mob: +1 301
252 7518
|
12 September
2008
-
Ends -
Item 12
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 196,522
ordinary shares of AstraZeneca PLC at a price of 2542 pence per share on 12
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,449,784,203.
G H R
Musker
Company
Secretary
15 September
2008
Item 13
ASTRAZENECA
AND TARGACEPT ANNOUNCE TOP-LINE RESULTS FROM PHASE IIB STUDY OF AZD3480 IN
ALZHEIMER’S DISEASE
|
·
|
Results
inconclusive, as primary outcome measure not statistically significant for
either donepezil or AZD3480; results impacted by improvement in placebo
group
|
|
·
|
Improvements
shown on secondary outcome measures ADCS-CGIC and
MMSE
|
|
·
|
Overall safety
and tolerability profile comparable to placebo, with fewer GI-related AEs
than donepezil
|
|
·
|
Next steps
include further analysis of full dataset and planned discussions with
leading medical experts
|
AstraZeneca and
Targacept, Inc. today announced that results from the Phase IIb clinical trial
of AZD3480 (TC-1734) conducted by AstraZeneca in mild to moderate Alzheimer’s
disease were inconclusive.
In the 12-week
placebo-controlled study, known as the Sirocco trial, neither the active
comparator donepezil nor AZD3480 met the trial’s criteria for statistical
significance on the primary outcome measure, ADAS-Cog (Alzheimer’s Disease
Assessment Scale – Cognition Subscale.) Both results were impacted by
an improvement in the placebo group.
At two of the three
doses tested, AZD3480 showed an improvement on the secondary outcome measures
ADCS-CGIC (Alzheimer’s Disease Cooperative Study – Clinical Global Impression of
Change, a 7-point scale), a widely accepted measure of clinician assessment of
change in patients’ behavior and ability to function, and MMSE (Mini Mental
State Examination, a 30-point scale), a quantitative cognition scale commonly
used by neurologists in a clinical setting. Of the three AZD3480
doses, the middle dose performed best on both measures (0.5 point improvement,
ADCS-CGIC and 0.9 point improvement, MMSE). Donepezil also showed an
improvement on ADCS-CGIC (0.2 point improvement) and the MMSE (1.0 point
improvement). Neither donepezil nor AZD3480 showed improvement in any
domain of the Cognitive Drug Research computerized test battery in the pooled
dataset of all subjects.
AZD3480 exhibited an
overall safety and tolerability profile comparable to placebo in the trial, with
fewer gastrointestinal-related adverse events (diarrhea, nausea and vomiting)
than donepezil.
Analyses of the full
dataset from the Sirocco trial are ongoing. AstraZeneca and Targacept
plan to discuss the data with leading medical experts and to present and publish
more detailed results over the coming months. A decision by
AstraZeneca with respect to potential further development of AZD3480 is expected
in December 2008.
“While we had hoped
for a more conclusive overall outcome, we believe the Sirocco trial provides
further support for the clinical rationale for AZD3480 by demonstrating
improvement on both ADCS-CGIC, an accepted scale that reflects improvement in
everyday activities, and the widely used MMSE cognitive assessment, as well as a
favorable safety and tolerability profile,” said J. Donald deBethizy, Ph.D.,
President and Chief Executive Officer of Targacept. “These findings
also strengthen the scientific foundation for our pipeline of NNR
Therapeutics. We thank AstraZeneca for its execution of this trial
and investment in the broad development of AZD3480.”
In addition to
Alzheimer’s disease, AZD3480 is currently being evaluated in a Phase IIb trial
in cognitive dysfunction in schizophrenia (the “HALO” trial), as well as a Phase
II exploratory study in adult attention deficit/hyperactivity
disorder. Top-line results from the cognitive dysfunction in
schizophrenia trial are expected by the end of 2008.
|
Media
Enquiries:
|
|
|
Neil
McCrae
|
+44 207 304
5045 (24 hours)
|
|
Chris
Sampson
|
+44 20 7304
5130 (24
hours)
|
|
Investor
Enquiries UK:
|
|
|
Jonathan
Hunt
|
+44 207 304
5087
|
mob: +44 7775
704032
|
|
Mina
Blair
|
+44 20 7304
5084
|
mob: +44 7718
581021
|
|
Karl
Hard
|
+44 207 304
5322
|
mob: +44 7789
654364
|
|
Investor
Enquiries US:
|
|
|
|
Ed
Seage
|
+1 302 886
4065
|
mob: +1 302
373 1361
|
|
Jorgen
Winroth
|
+1 212 579
0506
|
mob: +1 917
612 4043
|
|
Peter Vozzo
(MedImmune)
|
+1 301 398
4358
|
mob: +1 301
252 7518
|
About
the Study
The Phase IIb
Sirocco trial was conducted by AstraZeneca under the terms of an exclusive
global license and research collaboration agreement. The trial was a
multi-center, randomized, double blind, placebo controlled, dose-finding study
conducted at 84 sites in Western Europe, Eastern Europe and Canada. Subjects (n
= 567) were between 60 and 85 years of age and diagnosed with probable
Alzheimer’s disease that was classified, based on a quantitative scale, as mild
or moderate in severity. Subjects were assigned to one of three dose groups of
AZD3480, to an active comparator, donepezil, or to placebo and dosed over 12
weeks. The primary outcome measure in the trial was change from
baseline after 12 weeks on ADAS-Cog. A number of secondary outcome
measures were also used in the trial.
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in research, development,
manufacturing and marketing of prescription pharmaceuticals and supplier for
healthcare services. AstraZeneca is one of the world's leading pharmaceutical
companies with healthcare sales of US $29.55 billion and is a leader in
gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and
infection product sales. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index.
About
Targacept
Targacept is a
clinical-stage biopharmaceutical company that discovers and develops NNR
Therapeutics (TM), a new class of drugs for the treatment of central nervous
system diseases and disorders. Targacept’s product candidates selectively
modulate neuronal nicotinic receptors that serve as key regulators of the
nervous system to promote therapeutic effects and limit adverse side effects.
Targacept has product candidates in development for Alzheimer’s disease,
cognitive dysfunction in schizophrenia, pain and major depressive disorder, as
well as multiple preclinical programs. Targacept also has a cognition-focused
collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline.
Targacept's news releases are available on its website at
www.targacept.com.
16
September 2008
-
Ends -
Item 14
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 199,161
ordinary shares of AstraZeneca PLC at a price of 2503 pence per share on 15
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,449,585,327.
G H R
Musker
Company
Secretary
16 September
2008
Item 15
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 201,333
ordinary shares of AstraZeneca PLC at a price of 2477 pence per share on 16
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,449,391,198.
G H R
Musker
Company
Secretary
17 September
2008
Item 16
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 203,150
ordinary shares of AstraZeneca PLC at a price of 2453 pence per share on 17
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,449,188,048.
G H R
Musker
Company
Secretary
18 September
2008
Item 17
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 205,995
ordinary shares of AstraZeneca PLC at a price of 2417 pence per share on 18
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,448,982,053.
G H R
Musker
Company
Secretary
19 September
2008
Item 18
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 203,576
ordinary shares of AstraZeneca PLC at a price of 2448 pence per share on 19
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,448,778,477.
G H R
Musker
Company
Secretary
22 September
2008
Item 19
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 198,460
ordinary shares of AstraZeneca PLC at a price of 2517 pence per share on 22
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,448,580,366.
G H R
Musker
Company
Secretary
23 September
2008
Item 20
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 197,519
ordinary shares of AstraZeneca PLC at a price of 2530 pence per share on 23
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,448,385,791.
G H R
Musker
Company
Secretary
24 September
2008
Item 21
US
COURT DENIES TEVA’S MOTION FOR SUMMARY JUDGMENT IN
PULMICORT
RESPULES PATENT LITIGATION
AstraZeneca today announced that the US
District Court for the District of New Jersey has denied Teva’s Motion for Summary
Judgment of no infringement in the PULMICORT RESPULES (budesonide inhalation
suspension) patent litigation.
The court also
announced that a trial date will be scheduled and is likely to be in January
2009. AstraZeneca remains focused on preparing for this trial and is confident
in the strength of the intellectual property protecting PULMICORT
RESPULES.
In October of 2005,
AstraZeneca announced that it had filed a lawsuit in the US District Court for
the District of New Jersey against IVAX Pharmaceuticals, Inc. (now known as
Teva Pharmaceutical Industries
Ltd.) for patent infringement. The lawsuit is the result of an
abbreviated New Drug Application (ANDA) filed by Teva with the US Food and Drug
Administration (FDA) concerning its intent to market a generic version of
AstraZeneca’s PULMICORT RESPULES in the US prior to the expiration of
AstraZeneca’s patents in 2018, with pediatric exclusivity extending to
2019.
The FDA has not
approved a generic form of PULMICORT RESPULES, and has not yet responded to
AstraZeneca’s Citizen Petition, filed in 2006. The Petition outlined
AstraZeneca’s willingness to work with the FDA to ensure that any follow-on
budesonide inhalation suspension product is as safe and effective as PULMICORT
RESPULES.
|
Media
Enquiries:
|
|
|
Neil
McCrae
|
+44 207 304
5045 (24 hours)
|
|
Chris
Sampson
|
+44 20 7304
5130 (24
hours)
|
|
Investor
Enquiries UK:
|
|
|
Jonathan
Hunt
|
+44 207 304
5087
|
mob: +44 7775
704032
|
|
Mina
Blair
|
+44 20 7304
5084
|
mob: +44 7718
581021
|
|
Karl
Hard
|
+44 207 304
5322
|
mob: +44 7789
654364
|
|
Investor
Enquiries US:
|
|
|
Ed
Seage
|
+1 302 886
4065
|
mob: +1 302
373 1361
|
|
Jorgen
Winroth
|
+1 212 579
0506
|
mob: +1 917
612 4043
|
|
Peter Vozzo
(MedImmune)
|
+1 301 398
4358
|
mob: +1 301
252 7518
|
Notes to
Editors
PULMICORT RESPULES is a preventive,
maintenance asthma medicine indicated for use in children 12 months to 8 years
of age in the United
States. Full-year US sales
for PULMICORT in 2007 totalled $964 million, about 90 percent of which is
accounted for by PULMICORT RESPULES.
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in research, development,
manufacturing and marketing of prescription pharmaceuticals and supplier for
healthcare services. AstraZeneca is one of the world's leading pharmaceutical
companies with healthcare sales of US $29.55 billion and is a leader in
gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and
infection product sales. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index.
24
September 2008
-Ends-
Item 22
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 200,824
ordinary shares of AstraZeneca PLC at a price of 2486 pence per share on 24
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,448,192,287.
G H R
Musker
Company
Secretary
25 September
2008
Item 23
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 199,519
ordinary shares of AstraZeneca PLC at a price of 2503 pence per share on 25
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,447,994,279.
G H R
Musker
Company
Secretary
26 September
2008
Item 24
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 198,474
ordinary shares of AstraZeneca PLC at a price of 2518 pence per share on 26
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,447,796,835.
G H R
Musker
Company
Secretary
29 September
2008
Item 25
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
Further to the
announcement of its irrevocable, non-discretionary share repurchase programme
for the period 5 August 2008 to 30 September 2008, AstraZeneca PLC announced
that under the terms of that programme it purchased for cancellation 202,606
ordinary shares of AstraZeneca PLC at a price of 2463 pence per share on 29
September 2008. Upon the cancellation of these shares, the number of shares in
issue will be 1,447,594,229.
G H R
Musker
Company
Secretary
30 September
2008
Item 26
ASTRAZENECA
PLC IRREVOCABLE, NON-DISCRETIONARY SHARE REPURCHASE PROGRAMME
AstraZeneca PLC
today announced that, further to the announcement made on 5 August 2008 in
relation to an irrevocable, non-discretionary programme with Barclays Bank PLC
to purchase ordinary shares on AstraZeneca’s behalf during the period which
commenced on 5 August 2008 and was due to end on 30 September 2008, the
programme will be extended by one additional day and will end on 1 October
2008. Any purchases will be made within certain pre-set
parameters and in accordance with both AstraZeneca PLC's general authority to
repurchase shares and the Listing Rules.
G H R
Musker
Company
Secretary
30 September
2008
Item 27
Transparency
Directive
Voting
Rights and Capital
The following
notification is made in accordance with the UK Financial Services Authority
Disclosure and Transparency Rule 5.6.1. On 30 September 2008
the issued share capital of AstraZeneca PLC with voting rights is 1,447,598,473
ordinary shares of US$0.25. No shares are held in Treasury.
Therefore, the total number of voting rights in AstraZeneca PLC is
1,447,598,473.
The above figure for
the total number of voting rights may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, AstraZeneca PLC under the
FSA's Disclosure and Transparency Rules.
G
H R Musker
Company
Secretary
30
September 2008